As millions of women and men continue battling the impact of urinary tract infections (UTI), innovative, advanced technology therapies are progressing through clinical trials.
A recent Phase 2 trial evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli), reported positive news.
Read More
